Answer
Dupilumab (Dupixent) is indicated for children aged 6 months to 11 years with severe atopic dermatitis and adolescents aged 12 years and older with moderate-to-severe atopic dermatitis, provided they are candidates for systemic therapy.
Sources for this answer
- Dupixent 300 mg solution for injection in pre-filled syringeSANOFI · emc · SmPC §4.1 Therapeutic Indications · Version 27Document updated
Sources checked